Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NY57
UPID:
ST32B_HUMAN
Alternative names:
Yet another novel kinase 2
Alternative UPACC:
Q9NY57; Q6UXH3; Q8IY14
Background:
Serine/threonine-protein kinase 32B, also known by its alternative name, Yet another novel kinase 2, represents a crucial component in cellular signaling pathways. This protein, encoded by the gene with the UniProt accession number Q9NY57, plays a pivotal role in regulating various cellular processes through its kinase activity, which involves the phosphorylation of serine and threonine residues in target substrates.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase 32B could open doors to potential therapeutic strategies. Its involvement in key signaling pathways suggests that modulating its activity could offer new avenues for the treatment of diseases where these pathways are dysregulated.